Clinical Trial Update: A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy [Phase 2]

View source ↗

Summary

This Phase 2 trial compared two doses of Procrit (epoetin alfa) with a dose of Aranesp (darbepoetin alfa) in anemic cancer patients receiving chemotherapy. The …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Cancer

Drugs mentioned

• ARANESP (DARBEPOETIN ALFA)
• PROCRIT (ERYTHROPOIETIN)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Neoplasms, Anemia | Phase 2 | Status: TERMINATED | Results posted: 2009-06-01